key: cord-0694794-z0vkrfev authors: Hajiasgharzadeh, Khalil; Jafarlou, Mahdi; Mansoori, Behzad; Dastmalchi, Narges; Baradaran, Behzad; Khabbazi, Alireza title: Inflammatory reflex disruption in COVID‐19 date: 2022-04-29 journal: Clin Exp Neuroimmunol DOI: 10.1111/cen3.12703 sha: fc5c34642b57c4cb24f5ea233d10c3f915ccbdd8 doc_id: 694794 cord_uid: z0vkrfev Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was identified in Wuhan, China, in late 2019 and caused coronavirus disease 2019 (COVID‐19), which is still a global pandemic. In most infected people, SARS‐CoV‐2 can only cause moderate symptoms, while in other patients, it leads to severe illness and eventually death. Although the main clinical manifestation of COVID‐19 is often seen in the lungs, this disease affects almost all body organs. The excessive and prolonged release of inflammatory cytokines that may occur in COVID‐19 patients, known as cytokine storms, stimulates undesired immune responses and can cause various tissues damage. In the current review article, we focus on the potential advantages of the intrinsic cholinergic anti‐inflammatory pathway (CAP) as the efferent arm of inflammatory reflex in COVID‐19 management. Considering this endogenous protective mechanism against chronic inflammation, we focused on the effects of SARS‐CoV‐2 in the destruction of this anti‐inflammatory system. Several studies indicated the interaction of SARS‐CoV‐2 with the alpha7 subtype of the nicotinic acetylcholine receptor as the effector molecule of the inflammatory reflex. On the other hand, neurological manifestations have increasingly been identified as significant extrapulmonary manifestations of COVID‐19. The rational connection between these findings and COVID‐19 pathogenesis may be an important issue in both our understanding and dealing with this disease. COVID‐19 is deeply rooted in our daily life and requires an urgent need for the establishment of effective therapeutic options, and all the possible treatments must be considered for the control of such inflammatory conditions. Coronavirus disease 2019 and the virus that causes it (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) are two terms that have been heard every day for the past two years and have affected all aspects of our lives. This virus is responsible for the recent global viral pneumonia outbreak and has caused an unprecedented disaster around the world (1) . As of February 2022, COVID-19 has been confirmed in more than 420 million people worldwide. Dysregulated overproduction of inflammatory cytokines, which is known as cytokine storm, especially in the lung tissue, is one of the main features and hallmarks of COVID-19 (2) . However, the association between factors and parameters that lead to cytokine storms remains to be elucidated. Cytokine storm was not an easily manageable condition and contributed to mortality and morbidity in patients. During this pandemic outbreak, various treatments and drugs have been suggested to treat COVID-19 or reduce its symptoms (3) (4) (5) . Targeting cytokine overproduction in COVID-19 has been the subject of recent research, and some of them have had acceptable results (6) (7) (8) (9) , but most of the results are inconclusive due to the complexity of the processes. As a logical mechanism to control the release of the undesired cytokines, some studies investigated the role of the endogenous inflammatory reflex and the efferent arm of this reflex, which is called the "cholinergic anti-inflammatory pathway (CAP)" in the modulation of chronic inflammation (10) ( Figure 1 ). The alpha7 subtype of the nicotinic acetylcholine receptor (α7nAChR), as the effector molecule of the CAP, has a special significance in this mechanism (11) . Different cells or tissues expressing α7nAchR including the nervous system (12) , immune cells such as lymphocytes (13), monocytes (14) , and macrophages (15) , and many different tissues such as kidney (16) , bladder (17) , prostate (18) , testicular (19) , penile (20) , cervical (21) ovarian (22) , uterine (23), gastric (24) , colorectal (25) , pancreas (26) , liver (27) and lung tissue (28) . Regarding the activation of α7nAChR by nicotine, several studies have highlighted the low prevalence of smokers among COVID-19-infected patients (29) . Thus, nicotine and other α7nAChR ligands may have therapeutic value in hospitalized COVID-19 patients, however, the efficacy of such nicotine-based treatments is inconsistent (30, 31) . In addition to such interesting observation, to date, the CAP, as the efferent arm of the intrinsic inflammatory reflex, has been shown to inhibit the inflammator y response in many experimental and clinical experiments (32) (33) (34) . This is why we suggest considering these relevant issues and electrical or pharmacological activation of α7nAChR and potentiation of the CAP by inhibiting multiple inflammatory responses may protect against cytokine storm and thus have therapeutic value in COVID-19 patients and can be considered for the management of this global disaster. Here we provide a review of potential interactions between the CAP and SARS CoV 2 infection in humans, with an update on potential interactions between these protective responses and outcomes in patients with COVID-19. About two decades ago, Borovikova and colleagues mechanistically focused on the role of the central nervous system (CNS) in the regulation of systemic inflammatory responses and showed the existence of the CAP in an innovative animal study (35) . In their experiment, the production of TNF-α as a pro-inflammatory cytokine was decreased in an endotoxin-treated animal model that received electrical stimulation of the vagus nerve (35) . Further experiments revealed that such reflexive anti-inflammatory effects are exerted through multiple neuroimmune interactions, which is called the inflammatory reflex (36) . This reflex maintains immunological homeostasis through bidirectional communication between the brain and peripheral organs (37) . Recently, regulat io n of immune cell dynamics by the sympathetic nervous system has been reported (38) . The molecular mechanism by which the vagus nerve negatively regulates inflammatory responses has been identified, and the cellular and molecular basis for the regulation of the immune system by the nervous system has been demonstrated by Tracey et al (39) . The mechanism was found to be mediated by the nicotinic acetylcholine receptor α7 subunit, which is expressed on macrophages in the spleen. In the inflammatory reflex, the action of the afferent vagus nerve residing in the nodose ganglion is activated by inflammatory cytokines. The signal is moved to the nucleus tractus solitarius. Mutual associations between the nucleus tractus solitarius and the dorsal motor nucleus of the vagus nerve cause the activation of efferent vagus nerve fibers from the dorsal motor nucleus (40) . The signal is transmitted to the celiac ganglia and the superior mesenteric ganglion in the celiac plexus, where the nerve of the spleen originates. Norepinephrine released from this splenic nerve interacts with β2-adrenergic receptors and causes the release of ACh from ACh releasing T inflammation (40) . The detailed molecular mechanisms of inhibition of cytokine release by inflammatory reflex are investigated and highlighted in previous studies. Briefly, an extended range of inflammatory stimuli activates sensory neurons traveling to the brainstem through the afferent or sensory arm of the vagus nerve. After the transmission and arrival of these inputs to the brainstem, it generates action potentials that travel from the brain to the peripheral organs via the efferent or motor arm of the vagus nerve ( Figure 1 ). At the end of the inflammatory reflex mechanism, the direct or indirect activation of α7nAChR via ACh suppresses the production of inflammatory mediators. The action potentials cause the release of ACh from vagus nerve terminals as well as T cells containing functional choline acetyltransferase (40) . Then the produced ACh interacts with α7nAChR on immunocompetent cells to inhibit cytokine release (especially TNF, IL-1β, IL-6, and IL-18) from inflammatory cells (41) . The α7nAChRs are expressed in macrophages and B-and T-lymphocytes and as the effector molecule of the CAP may represent a neuroimmune target in inflammatory diseases (13) (14) (15) 42) . Early evidence in COVID-19 patients showed that the rate of infection in smokers is lower than general population suggesting potential protective effects of nicotine against SARS-CoV-2 (43-45). Alexandris et al. proposed that repurposing the approved drugs for smoking cessation and neurological conditions may be a therapeutic strategy in severe COVID-19 (46) . In addition to pharmacological activation of inflammatory reflex, electrical vagus nerve stimulation (VNS) is feasible and appears as an interesting tool in the treatment of inflammatory diseases and it seems that patients with a low vagal tone are more prone to complications of COVID-19 (47) . Many different studies have shown the benefit of pharmacological or electrical activation of the inflammatory reflex in the prevention of similar/related inflammatory conditions, e.g. acute respiratory distress syndrome (48, 49) . Also, numerous studies have suggested that electrical or pharmacological potentiation of CAP through α7nAChR activation, using VNS devices or exogenous α7nAChR agonists (such as nicotine or pharmacological compounds) could represent innovative therapeutic strategies to limit COVID-19-induced cytokine storm (50, 51) . Accumulated findings show that the inflammatory reflex drives a coordinated anti-inflammatory function and demonstrate that its anti-inflammator y potential may have therapeutic benefits against several bacterial and viral infections and holds promise for treating COVID-19. After the global outbreak of the COVID-19 pandemic, several experiments revealed that the SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) receptor as the receptor to enter the the virus and other cell receptors. There is a lot of evidence regarding the interactions between SARS-CoV-2 and nicotinic receptors (54) . The so-called cholinergic anti-inflammatory reflex is a construct that is standing on the α7nAChR. Some studies predict a direct interaction between SARS-CoV-2 spike glycoprotein with α7nAChR, which could impair the effectiveness of CAP and initiate the cascade of events in COVID-19 (55) . The data that the virus binds to the α7nAChR The autonomic nervous system (ANS) consists of complex antagonistic components and regulates many different physiological processes in response to internal or external stimuli. COVID-19 can cause several extrapulmonary manifestations including CNS damage and autonomic dysfunct io n is a prominent feature in moderate to severe COVID-19 disease (60,61). Table 1 summar ize different types, diagnostic methods, and range of complications of the nervous system in COVID-19 infection. The incidence range of nervous system complications varies in different studies and is calculated to be around 5-100% (Table 1 ). The immune system may influence ANS functio n and the local production of extremely high levels of inflammatory agents including cytokines, chemokines, and free radicals that cause severe damage to the lungs and other organs of the human body including ANS (62) . Both the sympathetic nervous system and parasympathetic nervous system may have been given a role in COVID-19, but here we are focusing on the parasympathe tic nervous system (63, 64) . Totally, autonomic dysfunction by impairing both afferent and efferent arms of the inflammatory reflex causes downstream effects that eventually benefit the virus or worsen the condition of the patient (65) . In this regard, heart rate variability in the evaluation of autonomic balance may provide an important source of information in COVID-19 (66) (67) (68) . Mao and colleagues investigated the neurological manifestations of SARS-CoV-2 infection which were observed in almost 40 percent of the infected patients (69) . Blood-brain barrier (BBB) breakdown as a potential mechanism of SARS-CoV-2-induced neurological dysfunction was proposed in some studies (70, 71) . Thus BBB breakdown may lead to infiltrating the peripheral cytokines to access the CNS where they may trigger or exacerbate neuroinflammation, as reported in some other experimental models, and could contribute to observed neurological manifestations and also increase susceptibility to autonomic dysfunction (72, 73) . In this regard, Liu et al. investigated the effects of stimulation of CAP in regulating autonomic functions and showed that VNS through nAChR is capable to improves pulmonary function in an animal model of lung injury (74). Abrams and colleagues' findings suggest that symptoms of small fiber neuropathy may develop during or shortly after COVID-19. Thus, autonomic dysfunction associated with COVID -19 infection may be derived from small fiber neuropathy and affects the function of CAP, and is associated with post-COVID-19 symptoms (75). The neurological manifestations of COVID-19 and autonomic dysfunction following COVID-19 infection were highlighted in some early-stage experime nts (76, 77) . More recently, the different aspects of autonomic dysfunction in SARS-COV-2 infect io n and the timeline of the main findings in the issue were reviewed (78, 79) . It seems that, up to 70% of survivors of COVID-19, the patients have one or more symptoms of post-viral autonomic dysfunction lasting for 3 months or greater, which highlights the importance of monitoring ANS symptoms (60) . Many efforts have been made to study the possibility to develop and use early suited to economically diagnose, and ideally predict COVID-19 outcome. Thus, some specific consequences and comorbidities associated with COVID-19 infection that are related to autonomic dysfunction can be prevented by inflammatory reflex stimulation (80) . But, detailed insights into the connection between vagal tone, autonomic dysfunction, and severity of COVID-19 should be investigated in future experimental and clinical studies. Last but not least, other reports are emerging suggesting the emergence of autoantibodies to G protein-coupled receptors in the autonomic nervous system. Dysregulation of these receptors of the autonomic nervous system may contribute to observed COVID-19 symptoms (81). Here we highlighted the autonomic dysfunction as a non-respiratory symptom in COVID-19 infection and points out the protracted inflammatory response due to the associated immunosuppressive dysfunction. Altogether, ANS can be affected during SARS-CoV-2 infection, and autonomic dysfunction may be a possible complication in COVID-19 individuals. As reviewed here, after highlighting the principles of the inflammatory reflex in maintaining immunological homeostasis, we focused on the inhibition of α7nAChR and autonomic dysfunctio n that both of which are caused by SARS-CoV-2 infection. This virus could interact with α7nAChR causing dysregulation of inflammatory reflex. Also, it can cause several extrapulmo nar y manifestations including autonomic dysfunction ( Figure 1 ). These manifestations may affect the endogenous protective mechanisms against deregulated pro-inflammatory cytokine secretion (82) . Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. This study received no specific grant from any funding bodies. Regarding the protective role of the endogenous inflammatory reflex, these two pieces of evidence about the effects of SARS-CoV-2 are significant in designing an efficient therapeutic strategy against COVID-19. COVID-19 Infection: Concise Review Based on the Immunological Perspective Infections-Therapeutic Strategies Targeting Cytokine Storm. Biomolecules Herbal medicine as an alternative method to treat and prevent COVID-19 -2 infection: The role of cytokines in COVID-19 disease Optimism and precautionary measures during the COVID-19 outbreak in China Colchicine and SARS-CoV-2: Management of the hyperinflammatory state Targeting Cytokine Storm in COVID-19: A Role of Online Hemodiafiltration with Asymmetric Cellulose Triacetate in Maintenance Hemodialysis Patients-A Report of 10 Cases A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection. Front Immunol Health Behaviors at the Onset of the COVID-19 Pandemic Physiology and immunology of the cholinergic antiinflammatory pathway Nicotinic Acetylcholine Receptors as Potential Tumor Biomarkers in Genitourinary Cancers: a Review Study. ImmunoAnalysis Alpha-7 Nicotinic Receptors in Nervous System Disorders: From Function to Therapeutic Perspectives Relationship between α7 nAChR and apoptosis in human lymphocytes Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-?B phosphorylation and nuclear factor-?B transcriptional activity through nicotinic acetylcholine receptor ?7 Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway Nicotine exposure and the progression of chronic kidney disease: role of the α7-nicotinic acetylcholine receptor Orally administered nicotine effects on rat urinary bladder proliferation and carcinogenesis Cholinergic α5 nicotinic receptor is involved in the proliferation and invasion of human prostate cancer cells Reduced testicular steroidogenesis in rat offspring by prenatal nicotine exposure: Epigenetic programming and heritability via nAChR/HDAC4 The expression, localization and function of α7 nicotinic acetylcholine receptor in rat corpus cavernosum Nicotine promotes cervical carcinoma cell line HeLa migration and invasion by activating PI3k/Akt/NF-κB pathway in vitro Nicotine inhibits MAPK signaling and spheroid invasion in ovarian cancer cells Nicotinic acetylcholine receptor agonists may be a novel therapy for endometriosis. Med Hypotheses Silencing A7-nAChR levels increases the sensitivity of gastric cancer cells to ixabepilone treatment Nicotine promotes cell proliferation via α7-nicotinic acetylcholine receptor and catecholamine-synthesizing enzymes-mediated pathway in human colon adenocarcinoma HT-29 cells Pancreatic Cancer Cells and Normal Pancreatic Duct Epithelial Cells Express an Autocrine Catecholamine Loop that Is Activated by Nicotinic Acetylcholine Receptors 3, 5, and 7 Sympathetic and parasympathetic innervation in hepatocellular carcinoma Alpha7 nicotinic acetylcholine receptors in lung inflammation and carcinogenesis: Friends or foes? From nicotine to the cholinergic anti-inflammatory reflex -Can nicotine alleviate the dysregulated inflammation in COVID-19? E-cigarette vape and lung ACE2 expression: Implications for coronavirus vulnerability E-cigaretteinduced pulmonary inflammation and dysregulated repair are mediated by nAChR α7 receptor: role of nAChR α7 in SARS-CoV-2 Covid-19 ACE2 receptor regulation Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis Chronic vagus nerve stimulation in Crohn's disease: a 6-month follow-up pilot study The endogenous inflammatory reflex inhibits the inflammatory response to different immune challenges in mice Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin The inflammatory reflex Reflex Principles of Immunological Homeostasis Anti-inflammatory reflex action of splanchnic sympathetic nerves is distributed across abdominal organs Mechanisms and Therapeutic Relevance of Neuroimmune Communication Neural regulation of immunity: molecular mechanisms and clinical translation Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation The role of nicotinic receptors in Blymphocyte development and activation A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications Nicotine and the nicotinic cholinergic system in COVID-19 How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection? Nicotinic cholinergic system and COVID-19: In silico evaluation of nicotinic acetylcholine receptor agonists as potential therapeutic interventions Targeting the cholinergic anti-inflammatory pathway with vagus nerve stimulation in patients with Covid-19? Bioelectron Med Non-invasive Auricular Vagus Nerve Stimulation as a Potential Treatment for Covid19-Originated Acute Respiratory Distress Syndrome Vagus nerve stimulation enhances the cholinergic antiinflammatory pathway to reduce lung injury in acute respiratory distress syndrome via STAT3 Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm. Front Immunol Expression pattern and function of SARS-CoV-2 Receptor ACE2. Biosaf Heal The impact of ACE2 genetic polymorphisms (rs2106809 and rs2074192) on gender susceptibility to COVID-19 infection and recovery: A systematic review Nicotinic receptors as SARS-CoV-2 spike co-receptors? Med Hypotheses Is SARS-CoV-2 Spike glycoprotein impairing macrophage function via α7-nicotinic acetylcholine receptors? Stimulation of α7 Nicotinic Acetylcholine Receptor by Nicotine Suppresses Decidual M1 Macrophage Polarization Against Inflammation in Lipopolysaccharide-Induced Preeclampsia-Like Mouse Model. Front Immunol Changes in alpha-7 nicotinic acetylcholine receptor and macrophage polarization state participate in the regulation of cervical remodeling in pregnant rats † Nicotinic cholinergic system and COVID-19: In silico identification of interactions between α7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-V and SARS-CoV-2 Spike glycoproteins Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications Autonomic dysfunction in post-COVID patients with and witfhout neurological symptoms: a prospective multidomain observational study Immune-mediated neurological syndromes in SARS-CoV-2-infected patients Sympathetic activation: a potential link between comorbidities and COVID-19 Clinical characterization of dysautonomia in long COVID-19 patients. Sci Rep Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19 Effects of COVID-19 lockdown on heart rate variability. Boullosa D, editor. PLoS One Describing heart rate variability in patients with chronic atrial fibrillation during hospitalization for COVID-19 Cholinergic Anti-Inflammatory Pathway and the Liver Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease Blood-Brain Barrier: COVID-19, Pandemics, and Cytokine Norms Th17 lymphocytes drive vascular and neuronal deficits in a mouse model of postinfectious autoimmune encephalitis Cross-talk between myeloid-derived suppressor cells and Mucin1 in breast cancer vaccination: On the verge of a breakthrough Regulating autonomic nervous system homeostasis improves pulmonary function in rabbits with acute lung injury Small fiber neuropathy associated with SARS-CoV-2 infection. M uscle N erve Autonomic dysfunction following COVID-19 infection: an early experience COVID-19 Dysautonomia. Front Neurol Neurological manifestations of COVID-19: A comprehensive literature review and discussion of mechanisms Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor's page series A Translational Perspective of Maternal Immune Activation by SARS-CoV-2 on the Potential Prenatal Origin of Neurodevelopmental Disorders: The Role of the Cholinergic Anti-inflammatory Pathway Dysregulation of G protein-coupled receptors of the autonomic nervous system, adrenergic and muscarinic acetylcholine receptors, in patients with autoimmune dysautonomic-related disorders Regulation of the acetylcholine/α7nAChR anti-inflammatory pathway in COVID-19 patients Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Neurologic Features in Severe SARS-CoV-2 Infection Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol Cerebrovascular Disease in COVID-19 New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: A retrospective multicenter study The authors declare that there is no conflict of interest.in COVID-19 infection.